• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager
• BL Club
• Smartbuy

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Hyderabad, Sept. 25 Pharma major Dr Reddy’s Laboratories Ltd has forayed into the inhaler segment by launching Combihale, a steroid and a long-acting broncho-dilator used in the treatment of asthma.

Available in two combinations — Combihale FF and Combihale FB — it comes in the forms of metered dose inhaler (MDI) and dry powder inhaler (DPI) with 120 doses, and as 30 blister capsule packs respectively.

A dry powder inhalation device (Redihaler) designed in-house by the Hyderabad-based company is also provided free of cost along with the broncho-dilator.

According to ORG IMS data, the inhaler market is currently valued at Rs 473 crore and is growing at over 17 per cent annually.

More Stories on : Announcements | New Products & Services | Dr. Reddy's Laboratories Ltd | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line